PRESS-RELEASE ·Filed Jun 4, 2026

EBS

Emergent BioSolutions
NEUTRAL
Impact 2/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release: contract
Actionable Insight • Neutral

This is a routine public awareness campaign with no financial data — no immediate trading catalyst. Monitor for future earnings or contract announcements that may quantify the commercial impact of naloxone product sales.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
EBS ▼ -29.98% at T+60d
NEUTRAL call ✗ call lost -29.98% · α vs SPY -31.86% · entry $8.44 → $5.91
Entry anchored
Jun 4, 2026
via day open
T+1d
-4.38%
call -4.38% · α -1.79%
$8.07
settled 4mo ago
T+5d
-0.59%
call -0.59% · α +1.96%
$8.39
settled 4mo ago
T+20d
-1.90%
call -1.90% · α -0.52%
$8.28
settled 3mo ago
T+60d
-29.98%
call -29.98% · α -31.86%
$5.91
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Emergent BioSolutions issued a press release announcing its partnership with Victoria's Voice Foundation for National Naloxone Awareness Day and promoting its NARCAN Nasal Spray and KLOXXADO products. The release is primarily a public awareness and branding initiative with no new financial data, contracts, or material business developments disclosed.

Key Facts

  • Emergent is the presenting sponsor of National Naloxone Awareness Day on June 6, 2026, in partnership with Victoria's Voice Foundation.
  • The company is continuing its 'Ready to Rescue' initiative at colleges and universities with spokesperson Zac Clark.
  • Emergent is the leading U.S. supplier of nasal naloxone, offering NARCAN Nasal Spray 4 mg (OTC) and KLOXXADO Nasal Spray 8 mg (prescription).
  • No financial figures, revenue, earnings, guidance, or deal values were disclosed in the press release.

Financial Impact

No financial impact disclosed or estimable from the press release content.

Risk Factors

  • Opioid overdose reversal market faces potential pricing pressure and regulatory changes.
  • Competition from generic naloxone products could erode market share.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3306708
16 reports for EBS
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+20▲ +14.89%Apr 29, 2026
Filters
Rows
Reports for EBS — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
Press Release
BEARISH ★ 7/10
$4.45 $5.68▼ −27.64%▼ −28.70%$6.29 (−41.35%)
Jun 29, 2026
13w ago
8-K
BULLISH ★ 5/10
$8.46 $7.26▼ −14.18%▼ −13.90%$6.29 (−25.65%)
Jun 4, 2026
17w ago
Press Release
NEUTRAL ★ 2/10
$8.44 $8.28▼ −1.90%▼ −0.52%$6.29 (−25.47%)
Apr 30, 2026
22w ago
Press Release
MIXED ★ 6/10
$8.47 $8.49▲ +0.24%▼ −5.05%$6.29 (−25.74%)
Apr 30, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.23 $9.18▲ +11.54%▲ +6.58%$6.29 (−23.57%)
Apr 29, 2026
22w ago
Press Release
BULLISH ★ 4/10
$7.99 $9.18▲ +14.89%▲ +8.85%$6.29 (−21.28%)
Apr 29, 2026
22w ago
Press Release
NEUTRAL ★ 1/10
$7.99 $9.18▲ +14.89%▲ +8.85%$6.29 (−21.28%)
Apr 28, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$8.23 $9.13▲ +10.94%▲ +5.47%$6.29 (−23.57%)
Apr 28, 2026
22w ago
Press Release
NEUTRAL ★ 4/10
$8.23 $9.13▲ +10.94%▲ +5.47%$6.29 (−23.57%)
Apr 27, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$8.23 $9.13▲ +10.94%▲ +5.47%$6.29 (−23.57%)
Showing 10 of 16

US Market Status

Market Open — Closes in 2h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 4, 2026